Bevacizumab significantly extended survival by nearly 4 months in patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard surgery and/or radiotherapy, according to the National Cancer Institute.
Bevacizumab extends survival in advanced cervical cancer